AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00280215
Drug: ACEI / Angiotensin converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
Trial: NCT00534976
Drug: Comparator: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily
Trial: NCT03724253
Drug: [68Ga]-NeoBOMB1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
Trial: NCT00426127
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03338296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT01342198
Drug: erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
Trial: NCT00615212
Drug: GSK376501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
Trial: NCT03808142
Drug: Betaferon, BAY86-5046
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT01725126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided as powder and Capsule.
Trial: NCT01128270
Drug: Dichloroacetate environmental dose
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
Trial: NCT01128270
Drug: Chloral Hydrate environmental dose
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
Trial: NCT02224703
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02224703
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03129126
Drug: LP-10
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical tacrolimus
Trial: NCT02859129
Drug: rosuvastatin 40 mg tablet
RxNorm normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
Trial: NCT02859129
Drug: Epanova™ QD (2 x 1 g capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
Trial: NCT02859129
Drug: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
Trial: NCT02859129
Drug: Multiple (20) oral doses of 2 g Vascepa® every 12 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
Trial: NCT00615212
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
Trial: NCT00002477
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002477
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04277884
Drug: Firibastat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration 2×250 mg capsules bid
Trial: NCT04277884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration 2 capsules bid
Trial: NCT01093469
Drug: EpiCeram
RxNorm normalized name: EPICERAM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03635099
Drug: Placebo (fasted)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Trial: NCT03635099
Drug: BI 25 mg (fasted)
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Trial: NCT03635099
Drug: BI 50 mg (fasted)
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Trial: NCT03635099
Drug: BI 100 mg (fasted)
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Trial: NCT03635099
Drug: BI 200 mg (fasted)
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
Trial: NCT03635099
Drug: Placebo (fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
Trial: NCT03635099
Drug: BI 200 mg twice daily, 400 mg total (fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
Trial: NCT01647308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
Trial: NCT02888574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT00047697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo used in placed of Donepezil HCL
Trial: NCT00468143
Drug: Adderall ® Immediate Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
Trial: NCT01582230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
Trial: NCT02297490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
Trial: NCT01229605
Drug: Cyclophosphamide and docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
Trial: NCT01162863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taken orally for 28 days
Trial: NCT01297530
Drug: BAY87-2243
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
Trial: NCT02855164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT00089466
Drug: AMD11070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMD11070 taken daily. Dosage dependent on arm.
Trial: NCT00709267
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00924742
Drug: Tapimycin (piperacillin 4 g + tazobactam 0.5g)
RxNorm normalized name: erythromycin stearate Oral Suspension [Arpimycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
Trial: NCT00483990
Drug: PSD502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01097213
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
Trial: NCT01681121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
Trial: NCT03446612
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 and 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
Trial: NCT01281839
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
Trial: NCT02273258
Drug: SAR342434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT01310231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops.
Trial: NCT04224402
Drug: mFOLFORINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Trial: NCT00630734
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg by mouth daily on days 1-4
Trial: NCT00630734
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg by mouth daily on days 15-18
Trial: NCT03916640
Drug: ADO09 formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of ADO09 formulation
Trial: NCT03916640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 0.9% NaCl
Trial: NCT03916640
Drug: Symlin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of pramlintide
Trial: NCT03916640
Drug: Humulin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of human insulin
Trial: NCT03916640
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of insulin lispro
Trial: NCT04977791
Drug: Anti-PD-1/PD-L1 monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observe a situation before and after immunotherapy
Trial: NCT00427570
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03446612
Drug: L-N-monomethyl arginine acetate (L-NMMA)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-N-monomethyl arginine acetate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
Trial: NCT02156323
Drug: RO7033877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of RO7033877 over 2.5 days
Trial: NCT02156323
Drug: RO7033877 + CMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of RO7033877 and CMS over 2.5 days
Trial: NCT01214642
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT00380302
Drug: AVE1625
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01201577
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250mg od
Trial: NCT02165813
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
Trial: NCT00032175
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02535975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets placebo PO three times a day for 24 weeks
Trial: NCT04307940
Drug: Naproxen Sodium (Aleve, BAY117031)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 220 mg per tablet, two tablets (440 mg), intake a single dose orally.
Trial: NCT04307940
Drug: Hydrocodone/Acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
Trial: NCT04307940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets, intake a single dose orally.
Trial: NCT03435601
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).
Trial: NCT01969682
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Trial: NCT02959112
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01037556
Drug: PR104
RxNorm normalized name: PR104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
Trial: NCT00127205
Drug: ibandronate sodium
RxNorm normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00127205
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00474721
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02181972
Drug: Gingko biloba
RxNorm normalized name: Gingko Biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03845140
Drug: L-PZQ ODT 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
Trial: NCT03845140
Drug: Biltricide®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.
Trial: NCT03845140
Drug: L-PZQ ODT 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.
Trial: NCT04291053
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment + Huaier Granule 20g po tid for 2weeks
Trial: NCT02088957
Drug: Phenytoin intravenous solution
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use
Trial: NCT02088957
Drug: Phenytoin oral tablets
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use
Trial: NCT00655330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01736358
Drug: Intranasal Ketoralac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery
Trial: NCT01736358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
Trial: NCT01340911
Drug: SRT3025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
Trial: NCT01340911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
Trial: NCT00050089
Drug: Standard ART vs Mega ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy vs Intensified therapy
Trial: NCT00443924
Drug: INS115644 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
Trial: NCT00443924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of placebo in each eye every 12 hours for three days
Trial: NCT00443924
Drug: INS115644 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Trial: NCT00443924
Drug: INS115644 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Trial: NCT00443924
Drug: INS115644 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
Trial: NCT02574845
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01093677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution placebo BID for 14 days.
Trial: NCT04039503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC as add-on to the pre-trial background medication.
Trial: NCT03596762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00643292
Drug: azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin SR 60 mg/kg x 1 dose
Trial: NCT02377713
Drug: KHK6640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose administration
Trial: NCT02377713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose administration
Trial: NCT02089568
Drug: Co-Amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will receive 1.2g co-amoxiclav at induction
Trial: NCT02089568
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 0.9% saline
Trial: NCT00227942
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo